A Phase 1b/2 Study of BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC).
Phase of Trial: Phase I/II
Latest Information Update: 01 Jul 2016
At a glance
- Drugs Dactolisib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 01 Jul 2016 This was originally designed as a phase Ib/II study; however, no patients were enrolled into the phase II part because of premature closure of the study.
- 01 Feb 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 09 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.